Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas

Alberto Ballestrero, Davide Boy, Roberta Gonella, Maurizio Miglino, Marino Clavio, Valentina Barbero, Alessio Nencioni, Marco Gobbi, Franco Patrone

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

To evaluate the safety and efficacy of pegfilgrastim administered as haematological support after autologous peripheral blood stem cell transplantation, we compared 44 patients with solid tumours and lymphomas receiving a 6-mg single dose of pegfilgrastim on day +5 after transplantation to a historical control group of 25 patients receiving filgrastim 5 μg kg-1 day-1 starting on day +5. There were no significant differences in haematological recovery nor in the incidence and duration of neutropenic fever. Median duration of grade 4 neutropenia in the pegfilgrastim and filgrastim group was similar. The incidence of grade III-IV mucositis was lower in pegfilgrastim than in filgrastim group due to the significant difference observed among the patients with solid tumours (p=0.00). The only adverse event considered to be cytokine related was mild to moderate bone pain occurring during haematological recovery. According to the present study design and taking into account the current prices in our institution, the cost of the two drugs was similar in both treatment groups. In conclusion, a single injection of pegfilgrastim administered at day +5 post-transplantation shows comparable safety and efficacy profiles to daily injections of filgrastim and may be cost effective.

Original languageEnglish
Pages (from-to)49-55
Number of pages7
JournalAnnals of Hematology
Volume87
Issue number1
DOIs
Publication statusPublished - Jan 2008

Fingerprint

Peripheral Blood Stem Cell Transplantation
Lymphoma
Neoplasms
Transplantation
Safety
Mucositis
Injections
Drug Costs
Incidence
Neutropenia
Fever
Filgrastim
pegfilgrastim
Cytokines
Costs and Cost Analysis
Bone and Bones
Pain
Control Groups

Keywords

  • Autologous bone marrow transplantation
  • Filgrastim
  • Lymphomas
  • Pegfilgrastim
  • Solidtumours

ASJC Scopus subject areas

  • Hematology

Cite this

Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. / Ballestrero, Alberto; Boy, Davide; Gonella, Roberta; Miglino, Maurizio; Clavio, Marino; Barbero, Valentina; Nencioni, Alessio; Gobbi, Marco; Patrone, Franco.

In: Annals of Hematology, Vol. 87, No. 1, 01.2008, p. 49-55.

Research output: Contribution to journalArticle

@article{7d8b402eeaef486c8bd4126f050c665a,
title = "Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas",
abstract = "To evaluate the safety and efficacy of pegfilgrastim administered as haematological support after autologous peripheral blood stem cell transplantation, we compared 44 patients with solid tumours and lymphomas receiving a 6-mg single dose of pegfilgrastim on day +5 after transplantation to a historical control group of 25 patients receiving filgrastim 5 μg kg-1 day-1 starting on day +5. There were no significant differences in haematological recovery nor in the incidence and duration of neutropenic fever. Median duration of grade 4 neutropenia in the pegfilgrastim and filgrastim group was similar. The incidence of grade III-IV mucositis was lower in pegfilgrastim than in filgrastim group due to the significant difference observed among the patients with solid tumours (p=0.00). The only adverse event considered to be cytokine related was mild to moderate bone pain occurring during haematological recovery. According to the present study design and taking into account the current prices in our institution, the cost of the two drugs was similar in both treatment groups. In conclusion, a single injection of pegfilgrastim administered at day +5 post-transplantation shows comparable safety and efficacy profiles to daily injections of filgrastim and may be cost effective.",
keywords = "Autologous bone marrow transplantation, Filgrastim, Lymphomas, Pegfilgrastim, Solidtumours",
author = "Alberto Ballestrero and Davide Boy and Roberta Gonella and Maurizio Miglino and Marino Clavio and Valentina Barbero and Alessio Nencioni and Marco Gobbi and Franco Patrone",
year = "2008",
month = "1",
doi = "10.1007/s00277-007-0366-7",
language = "English",
volume = "87",
pages = "49--55",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas

AU - Ballestrero, Alberto

AU - Boy, Davide

AU - Gonella, Roberta

AU - Miglino, Maurizio

AU - Clavio, Marino

AU - Barbero, Valentina

AU - Nencioni, Alessio

AU - Gobbi, Marco

AU - Patrone, Franco

PY - 2008/1

Y1 - 2008/1

N2 - To evaluate the safety and efficacy of pegfilgrastim administered as haematological support after autologous peripheral blood stem cell transplantation, we compared 44 patients with solid tumours and lymphomas receiving a 6-mg single dose of pegfilgrastim on day +5 after transplantation to a historical control group of 25 patients receiving filgrastim 5 μg kg-1 day-1 starting on day +5. There were no significant differences in haematological recovery nor in the incidence and duration of neutropenic fever. Median duration of grade 4 neutropenia in the pegfilgrastim and filgrastim group was similar. The incidence of grade III-IV mucositis was lower in pegfilgrastim than in filgrastim group due to the significant difference observed among the patients with solid tumours (p=0.00). The only adverse event considered to be cytokine related was mild to moderate bone pain occurring during haematological recovery. According to the present study design and taking into account the current prices in our institution, the cost of the two drugs was similar in both treatment groups. In conclusion, a single injection of pegfilgrastim administered at day +5 post-transplantation shows comparable safety and efficacy profiles to daily injections of filgrastim and may be cost effective.

AB - To evaluate the safety and efficacy of pegfilgrastim administered as haematological support after autologous peripheral blood stem cell transplantation, we compared 44 patients with solid tumours and lymphomas receiving a 6-mg single dose of pegfilgrastim on day +5 after transplantation to a historical control group of 25 patients receiving filgrastim 5 μg kg-1 day-1 starting on day +5. There were no significant differences in haematological recovery nor in the incidence and duration of neutropenic fever. Median duration of grade 4 neutropenia in the pegfilgrastim and filgrastim group was similar. The incidence of grade III-IV mucositis was lower in pegfilgrastim than in filgrastim group due to the significant difference observed among the patients with solid tumours (p=0.00). The only adverse event considered to be cytokine related was mild to moderate bone pain occurring during haematological recovery. According to the present study design and taking into account the current prices in our institution, the cost of the two drugs was similar in both treatment groups. In conclusion, a single injection of pegfilgrastim administered at day +5 post-transplantation shows comparable safety and efficacy profiles to daily injections of filgrastim and may be cost effective.

KW - Autologous bone marrow transplantation

KW - Filgrastim

KW - Lymphomas

KW - Pegfilgrastim

KW - Solidtumours

UR - http://www.scopus.com/inward/record.url?scp=36549090123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549090123&partnerID=8YFLogxK

U2 - 10.1007/s00277-007-0366-7

DO - 10.1007/s00277-007-0366-7

M3 - Article

C2 - 17710398

AN - SCOPUS:36549090123

VL - 87

SP - 49

EP - 55

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 1

ER -